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ABSTRACT
REPORTING OF RESULTS IN CLINICALTRIALS.GOV AND HIGH-IMPACT
JOURNALS: A CROSS-SECTIONAL STUDY.
Jessica E. Becker, Harlan M. Krumholz, Gal Ben-Josef, and Joseph S. Ross.
Section of General Medicine, Department of Internal Medicine, Yale
University School of Medicine, New Haven, CT.
In 2007, the FDA Amendments Act expanded requirements for ClinicalTrials.gov,
a public clinical trial registry maintained by the U.S. National Library of Medicine,
mandating results reporting within 12 months of trial completion for all FDA regulated
drugs. We compared clinical trial results reported on ClinicalTrials.gov with
corresponding published articles. We conducted a cross-sectional analysis of clinical
trials published from July 1, 2010 through June 30, 2011 in high impact journals (impact
factor ≥10) that were registered and reported results on ClinicalTrials.gov. We
compared trial results reported on ClinicalTrials.gov and within published articles for the
following: cohort characteristics, trial intervention, primary and secondary efficacy
endpoint definition(s) and results, and adverse events. Of 95 included clinical trials
registered and reporting results on ClinicalTrials.gov, there were 96 corresponding
publications, among which 95 (99%) had at least one discrepancy in reporting of trial
details, efficacy results, or adverse events between the two sources. When comparing
reporting of primary efficacy endpoints, 132 (85%) were described in both sources, 14
(9%) were described only on ClinicalTrials.gov, and 10 (6%) only within articles. Results
for 30 of 132 (23%) primary endpoints could not be compared because of reporting
differences between the two sources (e.g., tabular versus graphics); among the

remaining 102, reported results were discordant for 21 (21%), altering interpretations
for 6 (6%). When comparing reporting of secondary endpoints, 619 (30%) were
described in both sources, 421 (20%) were described only on ClinicalTrials.gov, and 1049
(50%) only within articles. Results for 228 of 619 (37%) secondary endpoints could not
be compared; among the remaining 391, reported results were discordant for 53 (14%).
Among published clinical trials that were registered and reported results on
ClinicalTrials.gov, nearly all had at least one discrepancy in reported results, including a
fifth among primary endpoints. Our findings question the accuracy of both sources and
raise concerns about the usefulness of results reporting to inform clinical practice and
future research efforts.
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I. INTRODUCTION

A. Evidence-Based Medicine: A History
Evidence-based medicine has become the approach of modern physicians in
delivering top-notch patient care. Defined as “the conscientious, explicit, and judicious
use of current best evidence in making decisions about the care of individual patients,”1
evidence-based medicine emphasizes combining clinical judgment from experience with
individual patients with data from studies that illuminate disease pathology and the
safety and efficacy of medical interventions. It calls for “weighing the pros and cons of
different treatments fairly.”2 While the term “evidence-based medicine” was first
introduced to the modern medical literature in 1991 by Gordon Guyatt of McMaster
Medical School in Ontario, Canada,3,4 this approach to patient care has been cited as far
back as the 9th century AD and in 19th century Europe.1,5 Yet, once Guyatt brought the
term into the literature, the academic importance of evidence-based medicine exploded.
By 2004, less than fifteen years after the term entered the literature, there were over 20
textbooks, nine academic journals, and several online tutorials dedicated to promoting
evidence-based medicine.3

B. Evidence-Based Medicine: The Importance of Clinical Trials
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In the era of evidence-based medicine, there are several methodologies of
obtaining clinical data that will be used to inform clinician decision-makers. These
include retrospective observational studies, case studies, and reviews of basic and
pathophysiologic research. The paragon of evidence informing practice, however, is the
randomized, controlled clinical trial.1,6-8 Indeed, since 1962, the United States Food and
Drug Administration (FDA) has regulated the approval of drugs on the basis of efficacy
and safety data from “adequate and well-controlled” clinical trials.9 Moreover,
approximately 20,000 new clinical trials of drugs and medical devices are registered
each year in the United States.10 These clinical trials represent a large investment in
both the public and private sphere. A 2006 Lancet study of 28 Phase III randomized
clinical trials funded by the NIH, for instance, found the cost of each trial ranged from
$722,000 to $64 million,11 or about $12 million per trial.12

C. Clinical Trial Results Dissemination
Clinical decision-making in a world of evidence-based medicine is complicated
and depends not only on physicians’ access to the most up-to-date data on drug safety
and effectiveness, but also on habit, personal experience, colleague experience, patient
preference, cost concerns, and other factors.13,14 It may be argued, however, that
whereas physicians’ personal experience with a medication or technology may play
heavily into the decision to stop using it in practice, the adoption of a new medication or
technology relies heavily on evidence and knowledge transfer, as the physician has no

personal experience with it.15 In a treatise on the diffusion, dissemination, and
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implementation of medical research into clinical decision-making, Lomas describes that
the steps of first making clinical trial data available, the subsequent analysis of the data
through meta-analysis and consensus statements, and ultimately the behavioral change
of physician decision-makers in their prescribing decisions is a process in which each
step relies on the previous step.14 Thus, though not sufficient to alter physicians’
medical decisions, the availability – or diffusion – of clinical data is a necessary step to
altering physicians’ medical decisions.14 Furthermore, because “research information…is
the core building block around which further efforts will be built,” Lomas argues that
“extensive attention” must be paid to the “validity and reliability of the research
information.”14 Thus, without disregarding the importance of factors like physicians’
willingness to change, patient preference, and clinical context of physician decisionmaking,13 it is the availability of safety and efficacy information on drugs and medical
innovations – which come from clinical trials – that is key to physician decision-making
and that forms the basis of evidence-based medical practice.
It usually takes the results of more than one trial to truly influence medical
practice.16 Rather than read through each new trial and analyze data individually,
however, most physicians rely on guidelines, consensus statements from professional
organizations, and meta-analyses to summarize and recommend new treatment
options.13,14,17 In fact, while it has been demonstrated that a single clinical trial may not
change clinical decision-making,18 recommendations put forth in consensus statements
have been estimated to have a conformation rate among physician decision-makers

averaging around 50 to 60 percent.18 Moreover, policymakers generally assume that
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guidelines put out by professional organizations will serve to spread new knowledge
about the effectiveness and safety of treatments.15 For instance, in the case of a new
recommendation from the U.S. Preventive Services Task Force (USPSTF) against the use
of prostate-specific antigen (PSA) as a screen for prostate cancer, Sen demonstrated
that PSA provision and ordering by physicians dropped substantially after the
recommendation release.15
In addition to demonstrating the effect of this institutional recommendation in
altering physicians’ behavior, Sen went on to demonstrate that physicians rely on one
another for practice decisions as well, by showing that the use of PSA by physicians in
the same group or practice as a given physician was significantly and positively
associated with PSA use by that physician.15 Nair et al. also find that the prescribing
behavior of expert “opinion leaders” has a significant impact on other physicians’
behavior within their networks – but only after new clinical guidelines are introduced.19
These studies indicate the importance of clinical evidence and its review by professional
organizations in driving not only individual physician decision-making, but also driving
decision-making among physician peers, which has safety and cost implications for an
even greater swath of patients. Given the widespread dissemination and influence of
clinical guidelines and their effect on medical decision-making, the full data picture must
be used by experts in order to develop the guidelines. While efforts have been made to
ensure the high quality of evidence that goes into consensus statements and

guidelines,20 it is equally important to ensure that complete evidence is available to
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guideline-makers and individual physicians alike.

D. Publication Bias
Throughout recent history, the main venue for accessing clinical trial results has
been in peer-reviewed medical journals.21,22 Ideally, for full efficacy and safety
information to reach the prescribing clinician decision-makers and professional
organizations creating clinical guidelines, all clinical trial results would be published
completely and accurately in the medical literature.8 Unfortunately, however, a growing
body of literature has indicated this is rarely the case. Frequently, the studies published
are only those with significant or positive results, a phenomenon termed “publication
bias.”23-32
The earliest modern evidence for this phenomenon comes from a 1959 paper by
Sterling, who demonstrated evidence of an unexpectedly large amount of studies with
statistically significant results in four psychology journals.30 More recently, many studies
have continued to show that positive studies are more likely to be published than
negative studies.7,23,25-28,30-33 One way of demonstrating publication bias is through
analysis of meeting abstracts, which has shown that clinical trial abstracts with positive
results are more likely to be published in full after the meeting.2,34,35 Another insight into
publication bias comes from looking at the length of time to publication. Among mostly
industry-funded research, it has been repeatedly found that 25% to 50% of clinical trials
are not published after several years. 7,22,31,33,36-40 Even among publicly-funded trials,

Ross et al. demonstrated that only 46% of a cross-section of NIH-funded clinical trials
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were published within 30 months of trial completion, with 68% published overall after a
median of 51 months after study completion.22 Moreover, multiple studies have shown
that time from trial completion to manuscript submission and to publication are
significantly faster among studies with positive results as compared to those with
negative results.7,28,32,39 Thus, a large share of the results from clinical trials of drugs and
devices, and particularly negative results, are delayed or never make it into the medical
literature, where they have the potential to impact healthcare decision-making.
Reasons for not publishing may include, but are not limited to, selective
publication, bias against reporting or publication of negative results, limited resources,
and a desire to publish “attention-grabbing” results – all both on the part of
investigators and of journal editors.2,7,22,36,37,41 Though journal editors play a role in
encouraging the publication of positive results, some evidence has demonstrated that
studies more often remain unpublished because they are never submitted, rather than
because they are rejected by reviewers.7,26 Selective publication, however, may also be
attributed to censorship by study sponsors, particularly in the case of pharmaceutical
trials that are funded by the drug or device manufacturer as compared to an outside
funding source.2

E. Outcome Reporting Bias
Even among clinical trials that are published, however, bias can exist in the data
that are available in the literature. Among such trials, the phenomenon of “outcome

reporting bias” – when only specific outcomes are included in the publication – has
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become increasingly recognized and problematic to a transparent medical evidence
base.7,42,43
As far back as 1986, Robert Simes used results from a clinical trial registry and
from the published literature to demonstrate differences in the suggested efficacy of
two chemotherapeutic agents.29 He looked specifically at trials registered in the
International Cancer Research Data Base (ICRDB), which at the time contained most
cancer-related clinical trials funded by the NIH. He reviewed the ICRDB registry, along
with the published literature, to examine the use of combination chemotherapy and
single agent therapy in two kinds of cancer. In each case, he performed a pooled
analysis and demonstrated that clinical trial results in the literature showed significant
benefits with the use of each of the combination chemotherapeutic regimens as
compared to the single alkylating agent. Pooling the results from the trial registry,
however, demonstrated no effect, or less of a positive effect, of the combination
chemotherapy as compared to the single agent regimen. Thus, he demonstrated a
selection bias in the publication of the outcomes previously registered in ICRDB that led
to a rosier picture of combination chemotherapy accessible to clinicians through the
medical literature than the data truly suggested.
Outcome reporting bias is not limited to the oncologic literature, however. While
the CONSORT Statement, first created in 1996 and updated as recently as 2010, lays out
guidelines for effectively and transparently publishing clinical trial data, selective
outcome reporting has continued to be demonstrated widely among published clinical

trial reports.8,44 In more recent studies comparing data submitted to the FDA to the
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published literature, important safety and efficacy information of drugs across a variety
of medical fields have repeatedly found to be lacking from the published
literature.37,41,45,46
The first systematic, comprehensive look at the issue of outcome reporting bias
in the literature came in 2004 from Chan et al., who compared trial protocols submitted
for Ethics Committee approval between 1994 and 1995 to the same trials published as
journal articles between 1995 and 2003.42 The group found that a striking 71% of trials
had at least one efficacy or safety outcome listed in the trial protocol that went
unreported in the corresponding publication; additionally, 62% had “major
discrepancies” between the primary endpoints laid out in the protocol and those
described in the corresponding publication.42 Such discrepancies suggest that
investigators or journal editors are shaping the medical literature to promote particular
outcomes, rather than allowing for the complete results to be analyzed in clinical
decision-making. Indeed, in this study, Chan et al. also surveyed trial authors, who cited
lack of statistical significance, journal space constraints, and low clinical importance as
the reasons that outcomes were selectively published.42 These reports were consistent
with the study’s finding that statistically significant outcomes were more than twice as
likely to be fully published than those that were not statistically significant, again
directly impacting the available medical evidence base to imply more positive drug
effects than the full data may really indicate.42

Chan and Altman went on to perform an additional study with quite similar
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results, examining primary and subsequent publications of clinical trials to identify
outcomes reported in the Methods section of at least one publication whose results
were never published in a Results section.47 Chan et al. additionally demonstrated
similar findings among a sample of exclusively federally-funded trials in Canada, with
88% of trials having at least one outcome going unreported in the publication and 40%
with discordant primary outcome specification between the trial protocol and
publication.48 This study indicated that, though financial incentives may play into the
desire to report only certain efficacy and safety outcomes in the published literature,16
selective outcome reporting is not limited to industry-funded trials.
In 2008, Turner et al. built on Chan’s work, examining phase 2 and 3 trials of 12
antidepressant medications that received FDA approval between 1987 and 2004.37 The
group examined data submitted to the FDA for marketing approval of these 12
medications, using the pre-specified trial protocols to evaluate the selective publication
of outcomes of those trials in the published literature.37 Turner uncovered wide-ranging
bias – including significantly higher rates of publication of trials with outcomes deemed
“positive” by the FDA as compared to those deemed “negative,” as well as the spinning
of results deemed “negative” by the FDA as positive in the literature.37 In fact, the team
found that results found to be positive by the FDA were 12 times as likely to be
published in agreement with the FDA analysis as compared to those deemed negative or
neutral by the FDA.37 The group went on to analyze how these discrepancies could pose
a threat to the validity of the studies in the published literature and found that tactics to

distort the results included using higher patient populations in the published sources;

10

increasing the effect size, with a median increase of 32%; and omitting or altering the
primary outcome from that pre-specified in the FDA protocol when publishing those
with an initially negative finding.37 Thus, this analysis further uncovered the threat to
the sanctity of science and the validity of the published literature when outcomes are
specifically selected to represent a story that may not be comprehensive and may even
be false.
Beyond these studies, others have found extensive evidence of outcome
reporting bias across medical specialties and countries. Ewart et al. compared trials
published in high-impact journals from late 2006 through early 2007 to entries in clinical
trial registries and found that nearly one-third had a change in the primary endpoint,
with the change most often being deletion.49 In a sample of trials published in highimpact journals in the fields of cardiology, rheumatology, and gastroenterology and
registered in a trial registry, largely of which was ClincalTrials.gov, Mathieu et al.
demonstrated that the primary trial outcomes registered varied from those that were
published in approximately 30% of trials; this number was consistent across general
medical and specialty journals and was similar to that found by Ewart et al.49,50 Fifteen
percent of the trials in this study had a primary outcome listed in the protocol that was
omitted from the publication.50 While only half of the discrepancies could be assessed
for clinical impact, of those that could, over 80% favored the reporting of a statistically
significant outcome in the publication, thus indicating the same bias that has been
demonstrated elsewhere.50 Dwan et al. found a higher rate of primary outcome
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inconsistency, 47 to 74 percent, in their review of studies examining outcome reporting
bias that compared trial protocols to publications.7 Two additional studies have also
demonstrated selective outcome reporting by showing significantly more complete
reporting of efficacy and safety results in trial registry entries as compared to
publications in a German sample and in a sample with registry entries on
ClinicalTrials.gov, respectively.51,52 Finally, Vedula et al. were able to go a step further
beyond trial protocols or registry reports to access internal documents from Pfizer and
Parke-Davis for trials of off-label use of gabapentin; they found that 8 of the 12 trials

that were published had a discordant primary outcome between the internal document
and the publication, thus demonstrating an even deeper-rooted issue in selective
outcome reporting.53
These studies highlight that, among a range of sources and medical specialties,
outcome reporting bias exists in the accessible medical literature and often exaggerates
the efficacy or safety of drugs. The lack of reporting, or altered reporting, of primary
endpoints in the published literature as compared to pre-specified protocols and
registry entries is particularly troubling, as trials are designed with statistical power to
address these outcomes as initially designated. Thus, the results of an altered primary
outcome when published may not be as statistically reliable. Additionally, patients sign
up for, and funders invest in, trials with particular clinical aims. Altering the primary
endpoint for publication can prevent advancement and true understanding in clinical
science to allow instead for the perceived advancement of academic or financial
interests when publishing more positive results.

E. The Problem with Bias
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Despite the mounting evidence that negative results are not published, at both
the study- and outcome-level, physicians and the institutions crafting clinical guidelines
need access to both positive and negative results in order to make fully informed,
evidence-based clinical decisions and recommendations.54 In fact, negative results are
instrumental in helping physicians to evaluate the medications they currently have at
their disposal and to “invalidat[e] previously accepted” medication usage.1,31
Additionally, literature reviews and meta-analyses depend on fully informed data.2,36,41
If trials or outcomes are selectively published, the numbers of patients can be difficult to
glean when using the published literature for meta-analysis or literature review.55
However, the complete story – positive and negative results – can only be revealed in
the setting of publication bias if clinical trial data can be freely accessed by clinicians
through mechanisms other than the published literature.
In addition to improving the quality and efficiency of evidence-based clinical
decision-making, other factors necessitate the public dissemination of clinical trial data.
Perhaps the most important of such factors is the ethical consideration to trial
participants.2,16,31,54,56 When patients participating in clinical trials give their time – and
their bodies – to research investigators, they generally do so with the assumption that
their donation of time and self will help to improve medical care for others. If the data
obtained from these patients are not fully or accurately conveyed to clinical decision
makers, the patient’s donation is for naught. Further, public dissemination of trial

results may also improve the trust of the general public in medical science as an
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institution.56
On top of clinical and ethical concerns, unpublished clinical trial results represent
a sunken investment. The cost of an individual phase III clinical trial has been estimated
in the hundreds of millions of dollars.57 The National Institutes of Health (NIH) spends
over $3.5 billion of public funds on investments in clinical trials.22 Thus, there is an
additional obligation from investigators funded by public sources to disseminate their
trial results in a freely-accessible, public setting.2 Whether publicly- or privately-funded,
unpublished research can also lead to the unbeknownst duplication of clinical trials,
further increasing the cost burden to the health care system.58

F. Policies to Address Bias: Clinical Trial Registration and Results Reporting
To tackle the issues of selective publication and publication bias, evidence-based
medicine experts have long supported the creation of broad-ranging public clinical trial
registries, with the goal of prospectively registering basic information about trials at trial
inception.2,29,31,55,56,58,59 As such, trial investigators and sponsors can be more readily
held accountable for not disseminating trial information and selectively reporting
results. While clinical trial registries have existed in one form or another since at least
the mid-1970s, the initial registries were generally specialty-specific, incomplete, and
difficult to access.60,61 The advent of the Internet age, however, has allowed for the
creation of online clinical trial registries, with the potential to disseminate all clinical trial
results in a complete and easily-accessible manner.60
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In 1997, the United States Congress passed the FDA Modernization Act (FDAMA),
mandating the Department of Health and Human Services, acting through the NIH, to
develop a public, Internet-based clinical trial registry, or “data bank[,]…of information
on clinical trials for drugs for serious or life- threatening diseases and conditions”

submitted to the FDA as part of Investigational New Drug (IND) applications.62,63 This law
compelled the U.S. Department of Health and Human Services to create a public registry
of ongoing, federally- and privately-funded clinical trials of drugs in the U.S. The law was
intended to provide a publicly-available listing of ongoing trials for patients who wished
to enroll, particularly those with rare illnesses who otherwise may not have knowledge
or access to groundbreaking treatments for their conditions. In addition to providing
information for patients, however, the registry was a first step in holding trial
investigators and sponsors accountable for providing public access to trial information,
an early step to improve transparency in the publicly-accessibly medical evidence base.
The initial requirements for the data bank, as laid out by the law, included:
“(A) A registry of clinical trials (whether federally or privately funded) of
experimental treatments for serious or life-threatening diseases and
conditions… Information provided shall consist of eligibility criteria for
participation in the clinical trials, a description of the location of trial
sites, and a point of contact for those wanting to enroll in the trial, and
shall be in a form that can be readily understood by members of the
public… (B) Information pertaining to experimental treatments for
serious or life-threatening diseases and conditions that may be
available-- (i) under a treatment investigational new drug application
that has been submitted to the Secretary under section 561(c) of the
Federal Food, Drug, and Cosmetic Act; or (ii) as a Group C cancer drug
(as defined by the National Cancer Institute). The data bank may also
include information pertaining to the results of clinical trials of such
treatments… including information concerning potential toxicities or

adverse effects associated with the use or administration of such
experimental treatments.”63
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Thus, on top of requiring basic information about each trial, the law suggests but did not
explicitly mandate the reporting of trial results and adverse events. Notably, device
trials were excluded from these mandates, with the explicit statement in the law that
including devices would be considered and possibly added.63
As a result of these requirements set out in FDAMA, the U.S. National Library of
Medicine launched a public, Internet-based clinical trial registry, ClinicalTrials.gov, in
2000. As laid out in the law, the registry was created on behalf of the National Institutes
of Health, under the Department of Health and Human Services. In addition to INDrelated trials, the new ClinicalTrials.gov database allowed for the registration of any
clinical trial, regardless of intervention kind, medical condition, or country of
investigation; and within five years, the ClinicalTrials.gov database contained over
20,000 trial entries.62 While other trial registries had been in place and subsequently
developed, including the WHO’s International Clinical Trial Registry Platform,
ClinicalTrials.gov has remained the largest and most prominent such registry in the
United States.54,56,60,61 While ClinicalTrials.gov did not initially require trial results to be
registered, the suggestion of including results laid out in FDAMA set the groundwork for
a potential publicly-available register of clinical trial results, which would later be
developed to improve access to trial data for clinical decision-makers and guidelinedeveloping institutions.
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In 2005, the International Committee of Medical Journal Editors (ICMJE), a group
of general medical journal editors who work to set recommendations for the conduct
and publication of medical research,64 initiated a policy that all trials being considered
for publication in one of its member journals must be registered in a public clinical trial
registry at or before patient enrollment.16 This move came explicitly in an attempt from
journal editors to start addressing the issues of publication and outcome reporting bias

and to improve clinical trial data transparency, with the policy announcement noting the
“ideal” that eventually “if all trials are registered in a public repository at their inception,
every trial’s existence is part of the public record, and the many stakeholders in clinical
research can explore the full range of clinical evidence.”16 The ICMJE defined clinical trial
at the time as “any research project that prospectively assigns human subjects to
intervention or comparison groups to study the cause-and-effect relationship between a
medical intervention and a health outcome.”16 At the time, ClinicalTrials.gov was, to the
knowledge of the ICMJE, the only established eligible registry fitting all requirements
laid out in their new policy, such as being freely accessible, open to all registrants, run
by a non-profit, and electronically searchable.16 Despite concerns from trial investigators
that this requirement would be taxing and eliminate competition,16 the number of
clinical trials registered in ClinicalTrials.gov jumped over 70% from 13,153 in the months
preceding the announcement to 22,714 trials just one month after the policy went into
effect in September 2005.56,62
In 2007, the ICMJE reevaluated this policy. At this time, the ICMJE broadened the
definition of clinical trial to that being used by the World Health Organization (WHO) –
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“any research study that prospectively assigns human participants or groups of humans
to one or more health-related interventions to evaluate the effects on health

outcomes”56 – in order to include preliminary trials in its mandate and thus in its goal of
improving trial transparency in the world of evidence-based medicine. The group also
endorsed the WHO ICTRP and its member registers as acceptable venues for clinical trial
registration.56 Recognizing a growing advocacy for reporting of clinical trial results to the
databases in which registration was required, the ICMJE specifically laid out in their
2007 announcement that “results posted in the same clinical trials registry in which the
primary registration resides…[would not be considered] to be previous publication if the
results [we]re presented in the form of a brief (<500 words) structured abstract or
table.”56 This move encouraged open access to trial results via trial registries while
reassuring investigators who might participate that their work would still be competitive
for publication.
In September of the same year, the U.S. Congress followed suit in utilizing the
developed ClinicalTrials.gov registry to create a database of publicly-accessible clinical
trial results, thus expanding the evidence base for clinical decision-making beyond
publications, by passing the FDA Amendments Act (FDAAA), Section 801.65 FDAAA
updated the clinical trial registry requirements that had been laid out under the 1997
FDAMA law. Specifically, FDAAA expanded the requirements to mandate registration by
trial sponsor or primary investigator at trial initiation for trials not only of drugs, as in
FDAMA, but also of all biologic agents and medical devices regulated by the FDA and of
pediatric postmarket surveillance studies required by the FDA.54,63,65,66 Notably, unlike

the new ICMJE requirement, FDAAA continues to exclude phase 1 clinical trials and
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“small feasibility studies” from reporting requirements.54,65,66 The law specifies that FDA
regulation applies to interventional trials with at least one arm; with one or more U.S.
sites; studying a drug, biologic, or device manufactured in the U.S. or its territories; or
that are conducted under an investigational new drug application or investigational
device exemption.65,66
More important, FDAAA mandates the reporting of the results of such trials
ongoing on or after September 27, 2007. Specifically, trial results must be uploaded to
ClinicalTrials.gov within 12 months of study completion, defined as completion of
collection of the primary endpoint on the final study subject.54,65 The specific data
elements that are required by this mandate include reporting of: the study design, start
date, target sample size, and the trial’s primary and secondary outcomes; demographic
and baseline characteristics of the sample, including enrollment and completion
numbers; results of the primary and secondary outcomes, including results of tests of
significance; and serious and frequent adverse events (>5% in any arm of the trial).54,65
The reporting requirements apply to the trial’s main results, not those of subgroup
analyses. The law also established penalties for not complying with the reporting of trial
information and results, including loss of NIH grant funding and fines of up to $10,000
per day.54,65 Results of trials of FDA-approved drugs being studied for a new,
unapproved indication have an additional year to report results; there is no requirement
to post results for drugs that never received FDA approval or for drugs that received FDA
approval before September 27, 2007 that no longer were the subject of clinical trials – a
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large majority of prescription drugs currently in clinical practice.54 Nonetheless, through
this new regulation, the U.S. government took a firm stance in supporting evidence-

based medicine by promoting clinical trial data transparency going forward. The law also
attempted to increase data clarity by laying out requirements for the Department of
Health and Human Services to link ClinicalTrials.gov entries to relevant results
information already available on the Internet through the FDA, National Library of
Medicine (NLM), or National Institutes of Health (NIH), such as FDA public health
warnings, FDA drug approval packages, or peer-reviewed articles linked through
Medline.54,65

G. Initial Evaluation of ClinicalTrials.gov
The mandated expansion of ClinicalTrials.gov under FDAAA to require results
reporting for studies investigating medical products created a pool of clinical trial
findings available to inform clinical practice and research. However, in a careful
evaluation of the new legislation, Alastair Wood points out that “because the submitted
data will not be peer-reviewed…interpreted, qualified, or explained, the results reported
at ClinicalTrials.gov will complement rather than replace the thoughtful presentation
and discussion of results characteristic of the best peer-reviewed publications.”54
Nonetheless, given the broad evidence base suggesting publication and outcome
reporting bias in peer-reviewed publications, ClinicalTrials.gov may very well serve as a
cache of data that may never make it into the peer-reviewed, published literature. As
such, analysis of the completeness and accuracy of the contents of the ClinicalTrials.gov
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registry after the implementation of FDAAA is important to ensure it can be a valuable
resource for clinicians and researchers.
Initial studies examining the contents of ClinicalTrials.gov after FDAAA have
indicated that despite the mandate and the purported penalties for non-compliance,
fewer than one-quarter of trials required to report results to ClinicalTrials.gov had
actually done so within a year of trial completion prior to 2011.67,68 However, in
subsequent years, the number of registered trials reporting results has increased.69
Previous studies have examined trial information available on ClinicalTrials.gov and
found fairly complete reporting of mandatory data elements, such as trial funder and

intervention, but high rates of missing data for optional elements and uncertainty about
information accuracy.41,50,62 Because results reporting began relatively recently under
FDAAA, no studies have yet thoroughly examined the completeness and accuracy of this
information on ClinicalTrials.gov.

II. Statement of Purpose
The purpose of this project is to evaluate the trial data and results reported to
ClinicalTrials.gov after the passing of the FDA Amendments Act and to examine how
these data on ClinicalTrials.gov compare to data published in the high-impact medical
literature for the same trials. While the results reported in either ClinicalTrials.gov or
published articles have the potential to be incomplete and inaccurate, inconsistencies
between these two sources of trial results will offer insights into whether and how
results reported for all trials, published or not, can be used to inform clinical practice
and future research efforts.
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III. Specific Hypothesis
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The results listed on ClinicalTrials.gov will be fairly complete for required data elements.
The clinical trial endpoints and results defined and reported on ClinicalTrials.gov will
vary from those in the published literature, in statistically significant ways, with a bias
towards positive results in the literature.

IV. Specific Aims
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Primary Aims:
1) To examine the completeness of trial results data reported on ClinicalTrials.gov
as required by FDAAA within 12 months of trial completion.
a. Specifically, to assess completeness of the following required data
elements: cohort characteristics; intervention; primary and secondary
endpoints; results of all primary and secondary endpoints; all serious
adverse events; and all other adverse events with a frequency ≥ 5% in at
least one study arm.
2) To better understand the accuracy of these trial data elements reported on
ClinicalTrials.gov, as compared to corresponding trial data elements published in
high-impact biomedical journals.

Secondary Aim:
1) To use secondary endpoint data reporting on ClinicalTrials.gov and in the
published literature to evaluate the existence of positive outcome reporting bias
in the published literature.
a. Specifically, to evaluate the significance of secondary endpoints listed on
ClinicalTrials.gov and to correlate secondary endpoint significance as
listed on ClinicalTrials.gov with publication of the endpoint in the trial’s
corresponding journal article.
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V. METHODS
A. Study Sample
Using information obtained from the NLM, members of the team (Dr. Ross and
Gal Ben-Josef) identified all articles published in a Medline-indexed journal between July
1, 2010 and June 30, 2011 that were linked to a ClinicalTrials.gov identification number
(n=4,586). These dates were chosen because we wanted to examine a one-year period,
data collection was set to begin in January 2012, and we wanted to allow for a lag
period after which investigators published their study to report results to
ClinicalTrials.gov. The information obtained from the NLM included all reported data
elements available on ClinicalTrials.gov, such as lead funder, study design, and condition
studied. From this sample of published clinical trials, Dr. Ross and Ms. Ben-Josef
identified a sub-sample of articles published in journals with an impact factor ≥ 10
(n=831), determined using Web of Knowledge (Thomson Reuters; New York, NY).
Subsequently, we restricted our study to articles describing clinical trials for which
results had been reported to ClinicalTrials.gov as of January 2012 (n=149). Finally,
because FDAAA only requires reporting of main trial results, we excluded 53 articles that
did not report main trial results or reported results of multiple trials (Figure 1).
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Figure 1: Flow diagram showing sample construction of clinical trials registered in and reporting main results on ClinicalTrials.gov
that were published in a Medline-indexed journal with an impact factor ≥ 10 between July 1, 2010 and June 30, 2011.
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B. Collecting Reported Information and Values
All data collection described below was performed by me (Jessica Becker). Gal
Ben-Josef assisted in data collection from a fraction of the trials. A selection of data was
also reviewed by Dr. Ross.

i. Cohort Characteristics and Trial Intervention
For each clinical trial, we collected information from both ClinicalTrials.gov and
the corresponding publication on cohort characteristics, including enrollment numbers,
completion numbers, and age and sex distributions, and the trial intervention. We
considered study intervention information incomplete unless the definition (i.e. name),
duration, frequency, and dosage of the intervention were each described.

ii. Primary Efficacy and Secondary Efficacy Endpoints
For each clinical trial, we collected the number of primary and secondary efficacy
endpoints reported on ClinicalTrials.gov and in the publication along with the definition
of each endpoint, including time point(s) at which the endpoint was measured and scale
defined to measure the endpoint’s results (e.g. a 54-point Attention Deficit
Hyperactivity Disorder rating scale or the defined threshold value for the endpoint). If an
outcome was reported at multiple time points, we considered each ascertainment point
separately. Since FDAAA mandates that only endpoints evaluated for the entire study
population be reported on ClinicalTrials.gov, we did not collect endpoints that were

defined only for a subgroup population or extension study endpoints. Next, for each
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endpoint, we collected results values reported on ClinicalTrials.gov and in the
corresponding publication and noted when values were not reported in one source or
the other.

iii. Adverse Events
For each trial, we collected the type and frequency of all serious adverse events
affecting one or more trial participants and all other adverse events with at least 5%
frequency in one trial arm from ClinicalTrials.gov and from the corresponding
publication, in concordance with ClinicalTrials.gov definitions.70

C. Comparing Reported Information and Values
All data collection and comparisons described below were performed by me
(Jessica Becker). Gal Ben-Josef assisted in data collection and comparison for a fraction
of the trials. A selection of data, including all results discordant between sources, was
also reviewed by Dr. Ross.

i. Cohort Characteristics and Trial Intervention
For each trial, we compared the reported information for cohort characteristics
and intervention between ClinicalTrials.gov and corresponding publications,
determining whether information was concordant, or in agreement. Each cohort

characteristic was considered concordant only if the values of the characteristic (e.g.
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number of participants enrolled or mean age) were numerically equal across sources for
all trial arms. We could not compare cohort characteristics when sources differed in
statistical analysis method, for instance, if one source reported medians and another
means. We considered reported study interventions concordant if there was agreement
in the definition, duration, frequency, and dosage of the intervention between both
sources.

ii. Primary Efficacy and Secondary Efficacy Endpoints
For each trial, we compared the reported information for primary and secondary
efficacy endpoints between ClinicalTrials.gov and corresponding publications. We
considered endpoint definitions concordant if there was agreement in the described
endpoint, time of endpoint ascertainment, and endpoint measurement scale between
both sources.
For primary and secondary efficacy endpoints that were reported in both
sources and defined concordantly, we determined whether results values were
concordant (i.e., numerically equal), discordant (i.e., not numerically equal), or could not
be verified. We could not verify results values when reporting was numerical in one
source but graphical in the other, sources differed in statistical analysis method, or
results were stratified differently between the sources.
For those primary efficacy endpoints with discordant results values, the medical
student author of this thesis (myself) and Dr. Ross evaluated the results together to

determine whether the publication’s values would lead to a different interpretation
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than the results reported on ClinicalTrials.gov would. We accomplished this by
examining the magnitude of the difference, directionality of the results, and statistical
significance testing from each source, when available. We did not examine the impact
on study interpretation for secondary efficacy endpoint results.

iii. Adverse Events
For each trial, we compared the reported information for adverse events
between ClinicalTrials.gov and corresponding publications, determining whether results
were concordant, discordant, or could not be verified. We considered serious and other
adverse event reporting concordant only if all serious events in one or more subjects or
all other events with a frequency ≥ 5% reported within one source were also reported in
the other, at equal numerical frequency for each event in all trial arms. We could not
verify adverse event results values when sources used different adverse event reporting
scales (e.g. serious and other categorization required by ClinicalTrials.gov versus the
National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE]
5-point graded scale in a publication) or if the publication combined serious and other
adverse events into one category.

D. Statistical Analysis
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All of the descriptive and statistical analyses described below, including the
exploratory analysis of secondary endpoints, were performed by me (Jessica Becker),
with assistance as needed and complete review both provided by Dr. Joseph Ross.
For sample description purposes, we collapsed the reported data elements
available on ClinicalTrials.gov into clinically meaningful categories (Table 1). We then
conducted a descriptive analysis, examining completeness of reported information on
ClinicalTrials.gov and concordance between ClinicalTrials.gov and corresponding
publications for trial cohort characteristics; intervention; primary and secondary
endpoints; primary and secondary endpoint results; all serious adverse events; and all
other adverse events with a frequency ≥ 5% in at least one study arm. For discordant
primary endpoint results, we also characterized the frequency with which trial
interpretation differed between the two sources.
As an exploratory analysis of secondary endpoints, to determine whether
favorable secondary endpoints were more likely to be reported in corresponding
publications, we classified the statistical significance of all secondary endpoints reported
on ClinicalTrials.gov and examined the likelihood of reporting statistically significant
endpoints in the corresponding publications using Chi-Square tests. In many cases,
statistical testing was reported within ClinicalTrials.gov. However, when not reported,
we performed statistical testing using reported results values, using QuickCalcs t test
calculator (v3.5.4, GraphPad; La Jolla, CA) for comparisons of continuous endpoints and
Epi Info™ (v7.1.1.0, Centers for Disease Control; Atlanta, GA) for comparisons of

categorical endpoints. A p-value ≤ 0.05 was used as a threshold for statistical
significance for superiority studies, > 0.05 for non-inferiority studies.
Descriptive analyses were performed using Excel® (v14.3.1, Microsoft
Corporation; Redmond, WA) and Chi-Square tests were performed using Epi Info™.
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VI. RESULTS
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A. Study Sample
We identified 96 trials reporting main results on ClinicalTrials.gov that were
published in a Medline-indexed journal with an impact factor ≥ 10 between July 1, 2010
and June 30, 2011. One ClinicalTrials.gov identifier registered a trial conducted in two
continents, with primary results for each continent published separately; for our
analysis, these articles were considered to be two separate trials. Industry was the lead
funder of nearly three-quarters of the trials (n=70; 73%). The most common conditions
studied were cardiovascular disease, hyperlipidemia, or diabetes (n=21; 22%), cancer
(n=20; 21%), and infectious diseases (n=19; 20%). Median trial enrollment size was 509
subjects (Inter-Quartile Range [IQR], 216–1281) and trials were most frequently
published by New England Journal of Medicine (n=23; 24%), Lancet (n=18; 19%), and
Journal of the American Medical Association (n=11; 12%). Table 1 below describes the
sample demographics in detail.

Table 1: Characteristics of clinical trials registered on ClinicalTrials.gov with primary results
published in a biomedical journal with impact factor ≥ 10 between July 1, 2010 and June 30,
2011.
Trial Characteristics
Trial Sponsor, No. (%)
Industry
NIH or other government agency
Non-profit organization or other funding agency
Phase 3 & 4 trials, No. (%)

70 (73)
9 (9)
17 (18)
68 (71)

Conditions examined, No. (%)
Diabetes, hyperlipidemia, or cardiovascular disease

21 (22)

Cancer

20 (21)

Infectious diseases

19 (20)

Neurologic

9 (9)

Hematologic

7 (7)

Other conditions
Trial enrollment size, median (range)

20 (21)
509 (216-1281)

Corresponding publication journal, No. (%)
New England Journal of Medicine

23 (24)

The Lancet

18 (19)

Journal of the American Medical Association

11 (12)

Other journal

44 (46)
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B. Data Completion
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All trials reported cohort enrollment, age, and sex distributions in both sources.
Trial completion rate was explicitly described in both sources, or could be calculated
from number enrolled and withdrawn, for 90 trials (94%). All trials provided some
intervention information in both sources; 16 (17%) were missing data on dosage
amount or timing in at least one source. For primary outcomes, 91 trials (95%) described
at least one primary efficacy outcome in both sources, whereas 5 (5%) had no primary
efficacy outcomes in either source, instead defining only primary safety outcomes in
both sources. Similarly, 94 publications (98%) and 89 ClinicalTrials.gov entries (93%)
described at least one secondary efficacy outcome, whereas 95 trials (99%) reported
adverse events in both sources.

C. Overall Registry-Article Comparison
Overall, 95 of 96 trials were found to have at least one discrepancy between
results reported to ClinicalTrials.gov and corresponding published articles: 29 (30%)
discordant trial cohort descriptions; 15 (16%) discordant intervention definitions; 27
(28%) discordant primary efficacy outcome definitions or results values; 91 (95%)
discordant secondary efficacy outcome definitions or results values; and 50 (52%)
discordant adverse events reporting. Table 2 below summarizes the completion and
comparison findings, while the sections below enumerate the comparison findings in
detail.
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Table 2: Reporting and comparison of results information on ClinicalTrials.gov and in

publications among trials published in a biomedical journal with impact factor ≥ 10 between July
1, 2010 and June 30, 2011 that were registered and reported results on ClinicalTrials.gov (n=96).
Results

Trials Reporting, No. (%)

Information

Comparison of Reported Information
among Trials Reporting in Both
Sources, No. (%)

ClinicalTrials.gov

Publication

Concordant

Discordant

Could Not
Be
Compared

Cohort
Characteristics
Enrollment No.

96 (100)

96 (100)

94 (98)

2 (2)

0 (0)

Completion Rate

90 (94)

90 (94)

70 (78)

20 (22)

0 (0)

Sample Age

96 (100)

96 (100)

56 (58)

6 (6)

34 (35)

96 (100)

96 (100)

85 (89)

9 (9)

2 (2)

96 (100)

96 (100)

65 (68)

15 (16)

16 (17)

Primary*

91 (95)

91 (95)

81 (61)

21 (16)

30 (23)

Secondary†

89 (93)

94 (98)

338 (55)

53 (9)

228 (37)

Distribution
Sample Sex
Distribution
Trial Intervention
Efficacy Endpoints

* For primary efficacy endpoints, same 91 trials defined a total of 156 primary efficacy endpoints
in either ClinicalTrials.gov or the corresponding publication, 132 (85%) of which were described
in both sources.

† For secondary efficacy endpoints, 96 trials defined a total of 2089 secondary efficacy
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endpoints in either ClinicalTrials.gov or the corresponding publication, 619 (30%) of which were
described in both sources.

D. Cohort and Intervention Registry-Article Comparison
Enrollment size could be compared for all 96 trials and was discordant for 2 (2%),
varying by 1 to 2 individuals per trial arm. We were able to compare trial completion
rates for 90 trials with complete information; of these, trial completion was discordant
for 20 (22%), with a median difference of 10.5 percentage points (IQR: 2.3-31.1). We
could not compare sex distributions for 2 trials (2%); among the remaining 94, sex
distribution was discordant for 9 (10%), with a median difference of 0.70 percentage
points (IQR: 0.17-4.7). We could not compare age distributions for 34 trials (35%);
among the remaining 62, age distributions were discordant for 6 (10%), varying by a
median of 0.60 years (IQR: 0.13-1.3). Among 80 trials with complete trial intervention
descriptions in both sources, 15 descriptions (19%) were discordant, most often because
of different dosages, different frequencies or duration of intervention, or description of
an additional intervention or placebo. See Appendix Table A1 for complete
enumeration of intervention discordances.

E. Primary Outcome Registry-Article Comparison
Among 91 trials defining primary efficacy endpoints, there were 156 endpoints
designated within either ClinicalTrials.gov or published articles, 132 (85%) of which were

described in both sources, 14 (9%) of which were described only on ClinicalTrials.gov,
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and 10 (6%) of which were described only in articles. The median number of primary
efficacy endpoints was 1 (IQR 1.0-1.0) per ClinicalTrials.gov entry and 1 (IQR 1.0-1.3) per
publication.
Thirty (23%) of 132 concordantly defined endpoints reported results values that
could not be compared, often due to graphical versus numerical reporting. Among 102
endpoints that could be compared, results values for 21 (21%) were discordant.
Therefore, in total, only 81 of 156 endpoints (52%) designated as primary efficacy
outcomes within either ClinicalTrials.gov or the published article were described in both
sources and reported verifiable and concordant results. Figure 2 below summarizes the
findings for primary endpoint reporting.
Among 21 trials with discordant primary efficacy outcome results values,
discrepancies led to differences in trial interpretation between sources for 6 (29%; 7% of
trials with primary efficacy endpoints). An example was reporting of statistically
different primary outcomes between trial arms on ClinicalTrials.gov but not significantly
different in the publication.71,72 Table 3 below highlights the primary endpoint results
discordances that altered trial interpretation.
For the remaining 15 trials (71%) with discordant primary outcome results
values, discrepancies did not lead to differences in trial interpretation. For instance, in
one case, primary endpoint results reported in the paper for the treatment group were
reported as results for the placebo group on ClinicalTrials.gov, and vice versa;73,74
however, since the results were not statistically different, trial interpretation was
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unchanged. In another instance, the discordant primary outcome results were close in
absolute value, in the same relative directionality between trial arms, and statistically
significant between trial arms in both sources.75,76 For a complete enumeration of the
primary endpoint results discordances that did and did not alter trial interpretation,
please refer to Appendix Table A2.
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Figure 2: Primary efficacy outcome endpoint definitions and results values reported on ClinicalTrials.gov and in corresponding journal articles
for clinical trials registered in and reporting main results on ClinicalTrials.gov that were published in a Medline-indexed journal with an impact
factor ≥ 10 between July 1, 2010 and June 30, 2011 (n=91).
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Table 3: Discordant primary efficacy endpoint results reported on ClinicalTrials.gov and in corresponding publication that altered trial
interpretation (n=6).
Trial ID

Primary Efficacy Outcome
ClinicalTrials.gov Reported Results

NCT00094887

Publication Reported Results

Median Hours to Resolution of Vaso-occlusive Pain Crisis (95% CI)

Explanation of Altered Trial
Interpretation
Time to resolution in both groups is

Inhaled Nitric Oxide: 61.83, 95% CI: (41.75,

Inhaled Nitric Oxide: 73.0, 95% CI: (46.0, 91.0);

substantially lower on

78.00); Placebo: 55.16, 95% CI: (46.00, 72.00); No

Placebo: 65.5, 95% CI: (48.1, 84.0); P = 0.87

ClinicalTrials.gov than in the article,
altering clinical interpretation.

statistical analysis provided.
Median Time to Progression (95% CI)

NCT00108953

Median time to progression in both

Sorafenib + Doxorubicin: 263 days, 95% CI: (146,

Sorafenib + Doxorubicin: 6.4 months, 95% CI:

groups is substantially higher on

384); Placebo + Doxorubicin: 147 days, 95% CI:

(4.8, 9.2); Placebo + Doxorubicin: 2.8 months,

ClinicalTrials.gov, altering clinical

(66, 244); P = 0.016

95% CI: (1.6, 5); P = 0.02

interpretation.

Number of Participants With Recurrence of Major Depression

NCT00177671

Percentage of participants with

Donepezil: 19/67, 95% CI: (16, 31); Placebo:

Donepezil: 35%; 95% CI: (24%, 46%); Placebo:

major depression recurrence is

11/63, 95% CI: (6, 18); HR=3.97, SD=2.09, 95% CI:

19%, 95% CI: (9%, 29%); HR=2.09, 95% CI: (1.00,

lower on ClinicalTrials.gov and

(1.00, 4.41); P=0.05

4.41), λ2=3.97; P=0.05

hazard ratio on ClinicalTrials.gov is 2fold greater.
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Progression-free Survival (PFS), median

NCT00281918

Fludarabine/Cyclophosphamide: 981.0 days,

Fludarabine/Cyclophosphamide: 32.8 months,

Range: (1, 1343); Fludarabine/

95% CI: (29.6, 36.0); Fludarabine/

Cyclophosphamide/Rituximab:

Cyclophosphamide/ Rituximab: 51.8 months, 95%

1212.0 days, Range: (1, 1372); P<0.0001

CI: (46.2, 57.6); P<0.0001

Roland Morris Disability Questionnaire, 1 year

NCT00404079

PFS is substantially lower in the
rituximab arm reported on
ClinicalTrials.gov than in the article,
altering clinical interpretation.

ClinicalTrials.gov score is higher for
both trial arms and statistical testing

Glucosamine Sulphate: 9, SD: 4; Placebo: 9, SD: 4;

Glucosamine Sulphate: 4.8, 95% CI: (3.9, 5.6);

Odds Ratio: 4.5 ± 4; P=0.05

Placebo: 5.5, 95% CI: (4.7, 6.4); P=0.50

results are different in the two
sources, leading to a difference in
trial interpretation.

NCT00426751

Number of Participants With Complete Sum ST Resolution 60 Min After Percutaneous Coronary
Intervention (Intent-to-Treat Population)

Confidence interval of the adjusted
difference between arms crosses

Eptifibatide: 124/214; Abciximab: 103/196;

Eptifibatide: 62.6%; Abciximab: 56.3%; Adjusted

zero on ClinicalTrials.gov and does

Adjusted Difference: 6.8%, 95% CI: (-3.0%, 16.6%)

Difference: 7.1%, 95% CI: (2.7%, 17.0%)

not in the article, suggesting a
difference in statistical testing of
results between the two sources,
leading to a difference in trial
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interpretation.

Note: NCT is term used by ClinicalTrials.gov when assigning a unique clinical trial identifier; CI=Confidence Interval
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F. Secondary Outcome Registry-Article Comparison
Among the 96 trials, there were 2089 endpoints designated as secondary
efficacy endpoints within either ClinicalTrials.gov or a published article, 619 (30%) of
which were described in both sources, 421 (20%) of which were described only on
ClinicalTrials.gov, and 1049 (50%) of which were described only in the article. There was
a median of 5 (IQR 2-12) secondary efficacy endpoints per ClinicalTrials.gov entry and 11
(IQR 7-21) per publication.
Among the 619 secondary endpoints defined in both sources, results of 228
(37%) could not be compared, often because results values were not reported within
ClinicalTrials.gov. Among 391 comparable secondary endpoints, 53 (14%) had discordant
results. Therefore, in total, only 338 of 2089 endpoints (16%) designated as a secondary
outcome within either ClinicalTrials.gov or the published article were described in both
sources and reported verifiable and concordant results. Figure 3 below summarizes the
secondary endpoint completion and comparison findings.
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Figure 3: Secondary efficacy outcome endpoint definitions and results values reported on ClinicalTrials.gov and in corresponding
journal articles for clinical trials registered in and reporting main results on ClinicalTrials.gov that were published in a Medlineindexed journal with an impact factor ≥ 10 between July 1, 2010 and June 30, 2011 (n=96).
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G. Secondary Endpoint Sub-Analysis
As a secondary analysis, we examined the likelihood of reporting statistically
significant endpoints in corresponding publications for the 1040 secondary efficacy
endpoints listed on ClinicalTrials.gov. Statistical significance could not be determined for
184 (18%) endpoints because results were not reported on ClinicalTrials.gov, the trial
only contained one arm, or results were in the form of a median or other summary
statistic that required the underlying distribution to determine statistical significance,
and no statistical analysis was provided on ClinicalTrials.gov. Among the remaining 856,
384 (45%) were statistically significant. However, only 559 (65%) of these 856 secondary
endpoints were reported in the publication, and secondary endpoints with statistically
significant results were more likely to be published when compared with endpoints
whose results were not statistically significant (71% versus 61%; Odds Ratio=1.60, 95%
CI=1.20-2.13, P=0.001).

H. Safety Outcome Registry-Article Comparison
Among 95 trials with adverse events results in both sources, we could not
compare serious adverse events for 33 (36%) and other adverse events for 31 (33%),
most often because of differences in severity stratification between the two sources.
Among 62 trials with comparable serious adverse events, 39 (63%) were discordant,
because of differing event criteria or frequency of reported serious adverse events.
Among 64 trials with comparable other adverse events, 46 (72%) were discordant,

because of differing event criteria, frequency, or frequency reporting threshold of
reported other adverse events. Overall, only 14 of 96 trials (15%) had concordant
serious and other adverse event reporting between the two sources.
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VII. DISCUSSION
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A. Summary
In a sample of 96 trials published during a recent one-year period in high-impact
journals that were registered within and reported results on ClinicalTrials.gov, we found
that results reporting information available on ClinicalTrials.gov, including descriptions
of the study cohort and intervention, as well as primary and secondary outcomes and
safety outcomes, was complete for more than 90% of registered trials. However, upon
comparing this information to the information provided in corresponding published
articles, nearly every trial had at least one discrepancy in the results descriptions or
values reported on ClinicalTrials.gov. Moreover, in many instances, results for both
sources could not be compared because of differences in the presentation or analysis of
the results. Our findings raise concerns about whether and which of the results
reported on ClinicalTrials.gov or in published articles were accurate and about the
usefulness of current clinical trial result reporting efforts to inform research and
practice, as publicly reported results at times disagree with, or even contradict, findings
reported in the peer-reviewed literature.
Many of the discrepancies between results reported on ClinicalTrials.gov and in
the published articles had important implications for clinical practice and interpretation
of trial findings. For instance, for some trials, the study intervention differed between
what was reported on ClinicalTrials.gov and the published article, leading to uncertainty
over how to interpret the results for practice. Similarly, a third of discordantly reported
primary outcome results led to different trial interpretation between the two sources

and no discrepancy of this nature should ever occur. Discrepant primary outcome
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definitions and results have obvious potential to confuse or potentially mislead
investigators, clinicians, and patients about the effectiveness of an intervention.
However, it is also important to note that many of the discrepancies observed were not
clinically meaningful. For instance, we observed minor discrepancies in the number of
subjects studied as well as in the results values reported for primary and secondary
outcomes and safety outcomes, many of which did not lead to different trial
interpretation between the two sources.

B. Setting in the Developing Literature
As compared to studies done prior to ours, our findings were similar in terms of
demonstrating outcome reporting bias in the published literature. Ewart et al., for
instance, found just over 30% of primary outcomes differed between trial registry –
including, but not limited to, ClinicalTrials.gov – and publications in high-impact journals
in a cross-section examined in 2007, before the passing of FDAAA.49 While we found
15% of primary outcomes were described discordantly between ClinicalTrials.gov and
the high-impact publications in our sample, it is promising that our rate was
approximately half of that found by Ewart et al. now that the FDAAA mandates are in
place.
Since the completion of our study, similar studies have come out in the
literature. In one, by Hartung et al., clinical trial results reported on ClinicalTrials.gov
were compared to those reported in corresponding journal publications for a random
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sample of phase 3 and 4 clinical trials.77 Unlike our study, which examined studies in the
highest-impact journals that likely represented a “best-case” scenario, this trial
examined a random sample with trials published in a variety of journals. Strikingly, and
reassuringly, our results were highly consistent with those uncovered by Hartung and
colleagues.
Indeed, Hartung and colleagues found that 15% of trials reported discrepant
primary outcome descriptions between ClinicalTrials.gov and corresponding

publications, whereas 20% inconsistently reported primary outcome values.77 We found
that 15% of primary outcomes were described inconsistently between ClinicalTrials.gov
and corresponding publications and 16% of primary results values were discordant
between the two sources. Hartung and colleagues also found that 35% of trials had
reporting discrepancies for serious adverse events.77 We, too, found that 41% of trials
had discrepant serious adverse event reporting. As in our study, this group similarly
found that inconsistencies were frequently due to underreporting or omission of
adverse events from publications. Whereas Hartung and colleagues found that 37% of
trials with at least one frequently reported adverse event in ClinicalTrials.gov had
discrepant adverse event reporting, we found slightly higher rates of these
discrepancies.77 Although the results reported on ClinicalTrials.gov and in corresponding
publications are not yet consistent, it is reassuring that the studies examining this issue
are.
Similarly, Killeen et al. published a study in Annals of Surgery to compare trial
registration and primary outcome reporting in trials published specifically in surgery

journals.78 Like ours, their sample came from studies published in the ten surgical
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journals with the highest impact factors, and all were either members of the ICMJE or
specifically required trial preregistration as a prerequisite to publication. However, the
trials in this sample were registered in several different clinical trial registries, including,
but not limited to, ClinicalTrials.gov. They found that that fewer than half of the 246
trials in their sample were adequately registered on ClinicalTrials.gov, which included
those that were registered after the study completion as well as those that did not have
a primary endpoint, had an unclear primary endpoint, or had a primary endpoint
without a defined timepoint in the registry entry.78 Among the 108 trials deemed to be
“adequately registered,” the group found that nearly 30% had a discrepancy between
the registered and published primary outcome, a number about twice as high as that
found in our sample of trials published across specialties.78 Among those results that
could be compared, the group found the discrepancy favored a positive result in over
90% of cases – a high, but perhaps not surprising, number.78 This finding was in line with
our secondary endpoint sub-analysis, which also suggested positive outcome reporting
bias among publications, as well as with previous findings in the literature.7 Another
study by Chahal et al. examining 34 clinical trials of operative and non-operative
interventions in the field of orthopedic surgery registered in ClinicalTrials.gov and
reported in publications showed that 80% had at least one discrepant piece of
information between the two sources, with 35% of trials having a discordance between
the registered and published primary endpoint.79 As shown by these two recent studies,
the findings in the specifically surgical world are not far off from, if not wrought by more
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discrepancy than, those in the high-impact general medical literature as demonstrated
by our work.

C. Implications
There are several possible explanations for the discrepancies we observed
between the results information and values reported on ClinicalTrials.gov and in
published articles. The most likely cause of these differences is reporting and
typographical errors. Results reporting is a relatively new phenomena and is the
responsibility of trial investigators and funders, who are less experienced with public
dissemination of their findings and may in fact have become accustomed to a system
where journal editors provide critical peer review and data checks to ensure accuracy.
Similarly, the space available to report results in published articles is limited, potentially
leading to incomplete reporting in articles while complete reporting is available on
ClinicalTrials.gov. While this explanation may justify some discrepancies in adverse
event reporting, particularly less serious adverse events, which have been shown to be
less likely to be published,80 it cannot account for the sizable discrepancy in secondary
endpoint reporting. Other possibilities include differing reporting requirements, such
that the format required by ClinicalTrials.gov may have differed from the journals,
possibly leading to re-analysis and error; or that results might have been posted to
ClinicalTrials.gov before the trial was completed, or alternatively have been published
before the final data set was locked.
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Lastly, and most worrisomely, discrepancies may also be due to investigators and
funders disseminating more favorable findings in published articles, which are more
likely to be read by clinicians and influence practice. We determined that statistically
significant secondary endpoint results were more likely to be included in published
articles, suggesting that investigators or publishers may be biased in the selection of
endpoints to include in publications. Thus, our work, along with the other recent
findings in the literature, raises important concerns that even with clinical trial
registration and results reporting, selective result reporting continues to distort the
medical evidence published in biomedical journals. Other examples of selectively
reporting favorable outcomes, even despite public availability of trial findings through
alternative sources, have been described.7,37,42,47-50,52
ClinicalTrials.gov has great potential to ensure the availability of complete and
comprehensive results of all studies investigating medical products to inform and
improve the practice of evidence-based clinical medicine, addressing known problems
with the slow and incomplete dissemination of research findings via peer-reviewed
published articles.22,38,39,41,81 However, our study raises questions about the accuracy of
the reported information, suggesting that further efforts are needed to improve the
information being made available to investigators, clinicians, and patients. One solution
may be to provide training to investigators and funders in the complete and accurate
reporting of trial results, or simply to increase the resources available to
ClinicalTrials.gov so that the organization could hire staff to input results for reporting.
Another may be to offer external peer review of the reported results, providing

independent review of study reports before public results reporting. Alternatively,
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review of the results on ClinicalTrials.gov could be routinely undertaken by journal
editors and reviewers upon receiving a trial for submission for publication. Finally,
perhaps investigators could make their clinical trial data available for public use,
allowing independent verification of the reported results,82 or at least Clinical Study
Reports or trial protocols, which can be similarly scrutinized and provide substantially
more information than published articles.31,52

D. Limitations
There are important limitations that must be considered when interpreting our
analysis. First, our study was limited to clinical trials that were registered and reported
results on ClinicalTrials.gov and had main results published in high-impact journals.
Despite studying a one year period, our sample for analysis only included 96 trials.
Moreover, since half of registered studies are never published41 and high-impact
journals are members of the International Committee of Medical Journal Editors, which
has been requiring clinical trial registration for nearly 10 years,16 our study may
represent the best case scenario in terms of the completeness and accuracy of results
reporting. Nevertheless, in this early period after FDAAA enactment when few trials are
reporting results,68 our results can be used to inform and improve the results reporting
system being used by ClinicalTrials.gov, ensuring its impact on clinical research and
practice. Additionally, we were conservative in our determination of results
concordance and discordance. We did not compare results when reporting was
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numerical in one source but graphical in the other, sources differed in statistical analysis
method, or results were stratified differently between the sources. Moreover, even
when differences were observed, we were cautious when determining whether these
differences would lead to different trial interpretation.

E. Conclusion
In conclusion, among trials published during a recent one year period in highimpact journals that were registered within and reported results on ClinicalTrials.gov,
we found that results reporting information available on ClinicalTrials.gov was
predominantly complete. However, upon comparing this information to corresponding
published articles, nearly every trial had at least one discrepancy in the results
descriptions or values reported on ClinicalTrials.gov, questioning the accuracy of both
sources and raising concerns about the usefulness of results reporting to inform clinical
practice and future research efforts.
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APPENDIX

Appendix Table A1: Trial intervention descriptions reported on ClinicalTrials.gov and in the corresponding
journal article that were determined to be discordant (n=15).
ClinicalTrials.gov
Identifier

Trial Intervention Descriptiona
ClinicalTrials.gov

Published Article

Trial Intervention
Discrepancy
Explanation

NCT00099268

Carbidopa/Levodopa/Entacapone:
Patients received Carbidopa/
levodopa/entacapone tablets. The
study was designed as a flexible
dose trial (200-1000 mg/day
levodopa). The target dose was
400 mg/day levodopa
administered orally as 4 equal
doses 4 times a day with 3.5-hour
dosing intervals for a treatment
period of 134 to 208 weeks.
Carbidopa/Levodopa: Patients

L-dopa/carbidopa in
both groups was
initiated at a dose of
50/12.5mg twice
daily, and titrated
to 100/25 (target
dose) or
150/37.5mg 4x daily
administered at 3.5hour intervals. For
patients in the LCE
group, entacapone
200mg was

Dosage of
intervention
ClinicalTrials.gov
states the levodopa
dose is flexible, up to
1000 mg/day, while
the article lists three
distinct doses with a
maximum of 600
mg/day levodopa.
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NCT00108953

NCT00141102

received Immediate release
carbidopa/levodopa tablets. The
study was designed as a flexible
dose trial (200-1000 mg/day
levodopa). The target dose was
400 mg/day levodopa
administered orally as 4 equal
doses 4 times a day with 3.5-hour
dosing intervals for a treatment
period of 134 to 208 weeks.
Sorafenib + Doxorubicin:
"Sorafenib + Doxorubicin" -combination therapy: Sorafenib
(Nexavar, BAY43-9006) 200 mg
tablets by mouth (orally) twice
daily + doxorubicin 60 mg/m2
intravenous infusion every 21
days for 6 cycles (18 weeks).

administered
with each LC dose.

Patients received 60
mg/m2 of
doxorubicin
intravenously every
21 days for a
maximum of 360
mg/m2 plus either
400 mg of sorafenib
or placebo orally
Placebo + Doxorubicin: "Placebo + twice
Doxorubicin" -- monotherapy:
daily.
Sorafenib (Nexavar, BAY43-9006)
matching placebo tablets by
mouth (orally) twice daily +
doxorubicin 60 mg/m2
intravenous infusion every 21
days for 6 cycles (18 weeks).
Celecoxib: 200 milligrams (mg)
Patients were
twice daily (BID) plus omeprazole randomly assigned

Dosage of
intervention
ClinicalTrials.gov
does not state
number of 200 mg
tablets and thus
suggests Sorafenib
and placebo dosing
at 400 mg/day, while
article states dosing
is 800 mg/day for
each.

Description of
placebo
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placebo and diclofenac slow
release (SR) placebo

NCT00154310

in a 1:1 ratio to
receive either
celecoxib 200 mg
Oral Diclofenac Plus Omeprazole: twice a day (Pfizer
Oral diclofenac SR (75 mg BID)
Inc, New York, NY,
plus omeprazole (20 mg once
USA) or diclofenac
daily [QD]) and celecoxib placebo. slow release 75 mg
twice a day
(Novartis
Pharmaceuticals UK
Ltd, Camberley, UK)
plus omeprazole 20
mg once a day
(AstraZeneca LP,
Westborough, MA,
USA) for 6 months.
Everolimus + Mycophenolate
Everolimus (0·75 mg
Sodium: Everolimus tablets orally twice a day, orally)
twice a day to maintain a level of was started the
6- 10 ng/mL and enteric-coated
day after the 4·5mycophenolate sodium orally
month assessment.
twice a day to achieve a target
Ciclosporin
dose of 1440 mg/day.
replacement was
Corticosteroids were added to the done in a stepwise
immunosuppressive regimen with manner (step 1:
a minimum dose of 5 mg
50%,
prednisolone or equivalent and
step 2: 25%, step 3:
had to be continued throughout
0) in 4 weeks or less.
the first year. Cyclosporine
Target trough

Additional celecoxib
placebo is described
on ClinicalTrials.gov
and not in the
article.

Dosage of
intervention
While target trough
concentrations of
everolimus are
concordant between
ClinicalTrials.gov and
the article, the
everolimus dosing
(0.75 mg twice daily)
is enumerated only
in the article and not
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concentrations of
everolimus were 3–
8 ng/mL in step 1
Cyclosporine + Mycophenolate
and 6–10 ng/mL
Sodium: Cyclosporine tablets
thereafter. Target
orally twice a day to achieve
ciclosporin
protocol specific target levels and concentrations
enteric-coated mycophenolate
were based on
sodium orally twice a day to
either C-0h (trough
achieve a target dose of 1440
concentration) or Cmg/day. Corticosteroids were
2h (drug
added to the immunosuppressive concentration 2 h
regimen with a minimum dose of after dose) in whole
5mg prednisolone or equivalent
blood, according to
and had to be continued
local practice. Up to
throughout the first year.
month 4·5 (time of
randomisation), C0h target was 150–
220 ng/mL, and C2h were 1100–1400
ng/mL for month 1,
950–1300 ng/mL for
month 2, and 800–
1200 ng/mL for
month 3 onwards.
From months 4·5–6
after
transplantation,
C-0h (and C-2h)
withdrawal started from Month
4.5 post-transplant.

on ClinicalTrials.gov.
Cyclosporine
numerical dosage is
not specified on
ClinicalTrials.gov,
while the target
levels are detailed in
full in the article.
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NCT00171210

Crossover: Participants treated
with Deferoxamine (DFO) during
the core study and crossed over
to receive Deferasirox (ICL670)
orally once a day during the

targets were 120–
180 ng/mL (700–
1000 ng/mL), and
after month 6, 100–
150 ng/mL (500–
800 ng/mL).
Corticosteroids were
mandatory (≥5
mg/day
prednisolone or
equivalent) and
were administered
according to local
practice. Target
dose of entericcoated
mycophenolate
sodium was 1440
mg/day, orally, for
both groups
throughout the first
year; dose
adjustments were
permitted.
Deferasirox dose
was initially
assigned according
to LIC [liver iron
concentration] at

Dosage of
intervention
Basis of dosage is
described as body
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NCT00177671

extension study. Dosage based on the start of
body weight.
deferasirox
treatment, whereby
ICL670: Participants treated with
patients with LIC
Deferasirox (ICL670) orally once a values of 2-3, > 3-7,
day during the core study and
> 7-14, and > 14 mg
continued this treatment in the
Fe/g dry weight (dw)
extension study. Dosage based on were assigned
body weight.
deferasirox doses of
5, 10, 20, or 30
mg/kg/ day,
respectively.
Donepezil: Treatment with
Patients initially
antidepressants (escitalopram
received open
(10mg to 20mg daily), venlafaxine antidepressant
(150mg to 300mg daily),
pharmacotherapy
duloxetine (20mg to 120mg daily) with escitalopram
plus donepezil (5mg to 10mg
oxalate (≤20 mg/d).
daily).
Those not
responding
fully were switched
Placebo: Treatment with
antidepressants (escitalopram
to a serotonin
(10mg to 20mg daily), venlafaxine noradrenergic
reuptake inhibitor
(150mg to 300mg daily),
duloxetine (20mg to 120mg daily) (duloxetine
plus placebo.
hydrochloride, ≤120
mg/d), followed as
needed by
aripiprazole

weight on
ClinicalTrials.gov and
LIC in the article.

Description of
intervention
Additional
antidepressants
include venlafaxine
on ClinicalTrials.gov
only and aripiprazole
in the article only.
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NCT00197106

NCT00243919

augmentation (≤15
mg/d) to achieve full
response.
Salmeterol/FP 50/100 Mcg Plus
Symptomatic
Placebo: One puff Salmeterol/FP
children were
50/100 mcg plus one puff placebo randomized to
(matching one puff of FP in the
either FP, 200 mg
200 mcg group) BID via DISKUS
twice a day Diskus
inhaler.
(FP group), or
salmeterol/FP,
50/100 twice a day
Diskus (SFP group),
for 26 weeks.
Early Locomotor Training
Locomotor training
Program: Stepping on a treadmill included stepping on
with partial body weight support
a treadmill with
and manual assistance as needed partial body-weight
for 20-30 minutes at 2.0 mph,
support and manual
followed by a progressive
assistance as
overground walking program for
needed for 20 to 30
20 minutes delivered at 2 months minutes at 3.2 km
post-stroke.
per hour (0.89 m per
second [2.0 mi per
Late Locomotor Training Program: hour]), followed by a
Stepping on a treadmill with
progressive program
partial body weight support and
of walking over
manual assistance as needed for
ground for 15
20-30 minutes at 2.0 mph,
minutes.
followed by a progressive

Description of
placebo
Additional placebo
described on
ClinicalTrials.gov.

Duration of
administration
Overground walking
program is described
as lasting 20 minutes
on ClinicalTrials.gov
and 15 minutes in
the article.
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NCT00255840

overground walking program for
20 minutes delivered at 6 months
post-stroke.
First line antiretroviral regimen
monitored by a HIV-trained
medical doctor:
1) Stavudine (>60 kg: 40 mg twice
daily and <60 kg: 30 mg twice
daily)
2) Lamivudine (150mg twice daily)
and
3) Efavirenz (600mg daily). For
women of child bearing potential
with a CD4+ count <250
cells/mm3, Nevirapine (200 mg
daily x 14 days, then 200 mg twice
daily) and for women with a CD4+
count > 250 cells/mm3,
Lopinavir/ritonavir (400/100mg
twice daily).

Regimens initially
prescribed by
the clinical safety
team included a
nucleoside
backbone
of stavudine and
lamivudine, with a
choice of efavirenz,
nevirapine, or
lopinavir plus
ritonavir. The initial
dose of stavudine
was 40 mg daily for
individuals weighing
more than 60 kg,
which was reduced
to 30 mg for all
patients
from mid-2007 in
line with WHO
recommendations.
Efavirenz was the
preferred nonnucleoside for men
and women not

Frequency of
administration
ClinicalTrials.gov
states stavudine
dosage is 80 mg or
60 mg per day, while
article states dosage
is 40 mg or 30 mg
per day.
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NCT00298766

Single Agent VELCADE:
Bortezomib 0.7, 1.0, 1.3 and 1.6

wishing to become
pregnant and willing
to maintain both
barrier and
hormonal
contraception
throughout the
study. Women of
childbearing
potential
were prescribed
nevirapine if their
CD4+ lymphocyte
count was less than
250 cells per μL, or
lopinavir plus
ritonavir if their
count was 250 cells
per μL or greater.
Pregnant women,
who were allowed
to enrol after their
first trimester, were
prescribed either
nelfinavir or
lopinavir plus
ritonavir.
Patients were
enrolled to receive

Dosage of
intervention
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mg/m^2 once weekly (QW) 4
doses in a 5 week cycle, and 0.7,
1.0, 1.3 mg/m^2 twice weekly
(BIW) 4 doses in a 3 week cycle

NCT00423670

PegIntron (1.5 μg/kg, once
weekly [QW]) plus ribavirin (800
to 1400 mg/day) for 48 weeks.

bortezomib at doses
up to 1.6 mg/m2 on
days 1, 8, 15, and 22
of 35-day cycles
(once-weekly
regimen) and then
at doses up to 1.3
mg/m2 on days 1, 4,
8, and 11 of 21-day
cycles (twice-weekly
regimen); details of
the phase 1 doseescalation
component
have been reported
previously.
Part 1 consisted of
five treatment
groups: one was a
control group in
which patients
received
peginterferon alfa2b 1·5 μg/kg plus
ribavirin 800–1400
mg per day for 48
weeks (PR48). Two
groups, the lead-in
groups, received

The article lists that
there are dosages up
to the maximum
dose, but only
enumerates the
maximum dose for
each cycle, while
ClinicalTrials.gov
enumerates all dose
amounts.

Frequency of
administration
PegIntron 1.5 μg/kg
dosage is described
as once weekly on
ClinicalTrials.gov but
appears to be daily
in the article.
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NCT00463567

peginterferon alfa2b 1·5 μg/kg and
ribavirin 800–1400
mg daily for 4
weeks (PR4)…
Indacaterol 150 μg (Continued
Patients received
Into Stage 2): In the morning,
double-blind
Indacaterol 150 µg once daily
indacaterol 150 or
orally inhaled via a single dose dry 300 mg or placebo
powder inhaler (SDDPI) + Placebo via single-dose dry
to Indacaterol delivered via
powder inhaler, or
SDDPI + Placebo to Formoterol
open-label
delivered via Aerolizer. In the
tiotropium 18 mg
evening, Placebo to Formoterol
via HandiHaler
delivered via Aerolizer.
(Boehringer
Participated in the 2 week Stage 1 Ingelheim,
and continued treatment up to 26 Ridgefield, CT).
weeks in Stage 2. Placebo to
(Blinded tiotropium
Formoterol inhalation in the
was not available.)
morning and in the evening was
Treatments were
taken once daily at
discontinued after Stage 1.
08:00 to 10:00.
Indacaterol 300 µg (Continued
Into Stage 2): In the morning,
Indacaterol 300 µg once daily
orally inhaled via a SDDPI +
Placebo to Indacaterol delivered
via SDDPI + Placebo to
Formoterol delivered via

Description of
placebo
Additional placebo
to Indacaterol is
described on
ClinicalTrials.gov but
not in the article.
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Aerolizer. In evening, Placebo to
Formoterol delivered via
Aerolizer. Participated in the 2
week Stage 1 and continued
treatment up to 26 weeks in
Stage 2. Placebo to Formoterol
inhalation in the morning and in
the evening was discontinued
after Stage 1.
Tiotropium 18 µg (Continued Into
Stage 2): Tiotropium 18 µg dry
powder capsules delivered (open
label) via manufacturer's
proprietary SDDPI, (Handihaler®).
Participated in the 2 week Stage 1
and continued treatment up to 26
weeks in Stage 2.
Placebo (Continued Into Stage 2):
In the morning, Placebo to
Indacaterol delivered via two
SDDPI devices + Placebo to
Formoterol delivered via
Aerolizer. In the evening, Placebo
to Formoterol delivered via
Aerolizer. Participated in the 2
week Stage 1 and continued
treatment up to 26 weeks in
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NCT00551642

Stage 2. Placebo to Formoterol
inhalation in the morning and in
the evening was discontinued
after Stage 1.
Inhaled Nitric Oxide (NO): Inhaled
NO administered by nasal
continuous positive airway
pressure, nasal cannula or face
mask at 5 parts per million (ppm)
for a maximum of 21 days
Placebo (Nitrogen): Placebo
Nitrogen gas administered by
nasal continuous positive airway
pressure, nasal cannula or face
mask at 5 parts per million for a
maximum of 21 days

NCT00642174

Prasugrel Then Clopidogrel:
Prasugrel: Oral prasugrel 60-mg
loading dose, followed by 6 to 9
days of prasugrel 10-mg/day
tablet maintenance dose.
Clopidogrel: Oral clopidogrel 600mg loading dose, followed by 6 to

Infants were given
inhaled nitric oxide
(5 parts per million
[ppm]) or placeboequivalent nitrogen
gas…Therapy was
given for at least 7
days, up to a
maximum of 21
days. If patients
needed mechanical
ventilation for less
than 7 days, therapy
was completed
through a nasal
continuous positive
airway pressure or
nasal cannula.
Patients who met all
criteria for
enrolment were
randomized at the
first visit to doubleblind treatment of
either prasugrel 60

Duration of
administration
The article lists a
minimum and
maximum duration
of inhaled NO, but
ClinicalTrials.gov
reports only a
maximum, implying
there is no minimum
duration.

Description of
placebo & Duration
of administration
Placebo tablets are
described in the
article but not on
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9 days of clopidogrel 150-mg/day
tablet maintenance dose.
Clopidogrel Then Prasugrel:
Clopidogrel: Oral clopidogrel 600mg loading dose, followed by 6 to
9 days of clopidogrel 150-mg/day
tablet maintenance dose.
Prasugrel: Oral prasugrel 60-mg
loading dose, followed by 6 to 9
days of prasugrel 10-mg/day
tablet maintenance dose.

mg LD
orally followed by 10
mg/day MD for 7
days or clopidogrel
600 mg LD orally [75
mg tablets Plavixw
(clopidogrel
bisulfate; Bristol–
Myers Squibb
/sanofi-aventis,
Bridgewater, NJ,
USA)] followed by
150 mg/day MD for
7 days (Figure
1A)…Patients were
administered an
equal number of
identical tablets for
either the LDs (six
prasugrel 10 mg
tablets and eight
placebo tablets
or eight clopidogrel
75 mg tablets and
six placebo tablets)
or MDs (one
prasugrel 10 mg
tablet and two
placebo tablets or

ClinicalTrials.gov.
ClinicalTrials.gov
states that dose
duration is 6 to 9
days, while the
article specifies a 7
day duration
explicitly.
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NCT00703118

two clopidogrel 75
mg tablets and one
placebo tablet).
T12/PR48: 12 weeks of 750 mg
Telaprevir (Tibotec)
telaprevir q8h followed by 4
was administered
weeks of Placebo in combination orally at a dose of
with 48 weeks of Peg-IFN-alfa-2a 750 mg every 8
and RBV at standard doses
hours;
peginterferon alfaT12(DS)/PR48: 4 weeks of Placebo 2a (Pegasys, Roche)
followed by 12 weeks of 750 mg
was administered
subcutaneously at a
telaprevir q8h in combination
with 48 weeks of Peg-IFN-alfa-2a dose of 180 μg per
and RBV at standard doses
week; and ribavirin
(Copegus, Roche)
was administered
Pbo/PR48: 48 weeks of Peg-IFNalfa-2a and RBV at standard
orally at a dose of
doses
1000 to 1200 mg
per day… In the
T12PR48 group, 266
patients were
assigned to receive
telaprevir,
peginterferon, and
ribavirin for 12
weeks, followed by
placebo plus
peginterferon
and ribavirin for 4

Description of
placebo & Dosage of
intervention
Additional placebo is
described for the
PR48 (control) group
in the article, but not
on ClinicalTrials.gov.
ClinicalTrials.gov
reports only that
doses are standard,
while the article
specifies numeric
values for dosing.
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weeks, and then
peginterferon plus
ribavirin alone for
32 weeks. In the
lead-in T12PR48
group, 264 patients
were assigned to
receive placebo,
peginterferon, and
ribavirin for 4
weeks, followed by
telaprevir plus
peginterferon
plus ribavirin for 12
weeks, and then
peginterferon plus
ribavirin alone for
32 weeks. In the
PR48 (control)
group, 132 patients
were assigned to
receive placebo,
peginterferon, and
ribavirin for 16
weeks, followed by
peginterferon plus
ribavirin for 32
weeks. In all the
groups, study drugs
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were administered
for 48 weeks.
a Entries

in the Trial Intervention Description columns are taken verbatim from ClinicalTrials.gov and the corresponding article,

respectively, for each ClinicalTrials.gov identifier provided (emphasis added by this author).
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Appendix Table A2: Primary efficacy outcome results values reported on ClinicalTrials.gov and in the corresponding journal article
that were determined to be discordant (n=21).
ClinicalTrials.gov
Identifier and

Primary Efficacy Outcome Results
ClinicalTrials.gov

Published Article

Difference in Trial
Interpretation due to

Primary Efficacy

Discrepancy?

Outcome
NCT00090285

qHPV Vaccine: 0.1

qHPV Vaccine: 0.11

No

Incidence of
Human
Papillomavirus
(HPV) Related
External Genital
Warts, Perineal
Intraepithelial
Neoplasia (PIN),
Penile, Perianal
or Perineal
Cancer,
incidence per
100 person-years

Placebo: 1.0

Placebo: 1.10

Percent relative risk

Observed efficacy:

reduction: 90.6

90.4%

95% CI: (70.1, 98.2)

95% CI: (69.2%, 98.1%)

The incidence values
and observed efficacy
are very similar
between sources,
likely with a similar
test of statistical
significance.

P<0.001
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NCT00094887

Inhaled Nitric Oxide: 61.83

Inhaled Nitric Oxide: 73.0

Yes

Time to
Resolution of
Vaso-occlusive
Pain Crisis (VOC),
median hours
(95% CI)

95% CI: (41.75, 78.00)

95% CI: (46.0, 91.0)

Placebo: 55.16

Placebo: 65.5

95% CI: (46.00, 72.00)

95% CI: (48.1, 84.0)

No statistical analysis

P = 0.87

The time to resolution
in both groups is
substantially lower on
ClinicalTrials.gov than
in the article, with the
treatment time on
ClinicalTrials.gov
lower than the
placebo time in the
article, even if the test
of statistical
significance was likely
the same in both
sources.
Yes

provided.

NCT00108953

Sorafenib + Doxorubicin:

Sorafenib + Doxorubicin:

Time to
Progression,
median

263 days

6.4 months

95% CI: (146, 384)

95% CI: (4.8, 9.2)

Placebo + Doxorubicin:

Placebo + Doxorubicin:

147 days

2.8 months

95% CI: (66, 244)

95% CI: (1.6, 5)

The median time to
progression in both
groups is substantially
higher on
ClinicalTrials.gov (9.6
and 4.8 months,
respectively), even if
the test of statistical
significance between
the groups was the
same in both sources.
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NCT00177671

P = 0.016

P = 0.02

Donepezil: 19/67

Donepezil: 35%

Yes

95% CI: (24%, 46%)

Number of
95% CI: (16, 31)
Participants With
Recurrence of
Placebo: 11/63
Major
Depression
95% CI: (6, 18)

NCT00262080

HR = 3.97

HR = 2.09

SD = 2.09

95% CI: (1.00, 4.41)

95% CI: (1.00, 4.41)

λ2=3.97

P = 0.05

P = 0.05

The percentage of
participants with
major depression
recurrences is lower
(28.4% and 17.5%,
respectively) on
ClinicalTrials.gov than
in the article, and the
hazard ratio listed on
ClinicalTrials.gov is 2fold higher than that
listed in the article
(3.97 vs. 2.09).

Ecallantide: 49.5

Ecallantide: 46.8

No

SD: 59.3

The absolute
treatment outcome
score and difference
between arms is
similar in both
sources, and the test
of statistical

Treatment
SD: 59.43
Outcome Score
at 4 Hours Post- Placebo: 18.5
Dose, mean units
SD: 67.78

Placebo: 19%
95% CI: (9%, 29%)

Placebo: 21.3
SD: 69.0
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P = 0.037

P = 0.004

significance shows a
significant difference
in both sources.

NCT00281918

Fludarabine/Cyclophospha

Fludarabine/Cyclophosphami

Yes

Progression-free
Survival (PFS),
median

mide:

de:

981.0 days

32.8 months

Range: (1, 1343)

95% CI: (29.6, 36.0)

Fludarabine/Cyclophospha

Fludarabine/Cyclophosphami

mide/

de/

PFS is substantially
lower in the rituximab
arm reported on
ClinicalTrials.gov (39.8
months) than in the
article, even if the test
of statistical
significance is the
same in both sources.

Rituximab:

Rituximab:

1212.0 days

51.8 months

Range: (1, 1372)

95% CI: (46.2, 57.6)

P<0.0001

P<0.0001

NCT00335452

Clopidogrel + ASA Low

Clopidogrel + ASA Low Dose:

No

First Occurrence
of CV Death / MI
/ Stroke - ASA

Dose:

549/12,579

The composite
primary outcome
results are quite close,
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Dose
Comparison

546/12,563

Clopidogrel + ASA High Dose:

Clopidogrel + ASA High

530/12,507

Dose:

P = 0.61

with nearly identical
tests of significance, in
the two sources.

527/12,498
P = 0.6047
NCT00377260

Amoxicillin-Clavulanate:

Amoxicillin-Clavulanate: 61%

No

The Time to
Resolution of
Symptoms,
Defined as Acute
Otitis MediaSeverity of
Symptoms
(AOM-SOS)
Score of 0 or 1,
According to
Treatment
Assignment, Day
4, participants
NCT00377260

87/144

Placebo: 54%

Placebo: 78/147

No statistical analysis

No statistical analysis

provided for this timepoint.

ClinicalTrials.gov
percentages (60.4%
and 53.1%,
respectively) are very
similar to those in the
article, likely with a
similar test of
statistical significance.

Amoxicillin-Clavulanate:

Amoxicillin-Clavulanate: 80%

No

The Time to
Resolution of

114/144

Placebo: 74%

ClinicalTrials.gov
percentages (79.1%

provided for this timepoint.
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Symptoms,
Defined as Acute
Otitis MediaSeverity of
Symptoms
(AOM-SOS)
Score of 0 or 1,
According to
Treatment
Assignment, Day
7, participants

Placebo: 106/147

No statistical analysis

No statistical analysis

provided for this timepoint.

NCT00377260

Amoxicillin-Clavulanate:

Amoxicillin-Clavulanate: 41%

No

The Time to
Resolution of
Symptoms,
Defined as Acute
Otitis MediaSeverity of
Symptoms
(AOM-SOS)
Score of 0 or 1
on Two
Consecutive
Occasions,
According to
Treatment

58/144

Placebo: 36%

Placebo: 51/147

No statistical analysis

No statistical analysis

provided for this timepoint.

ClinicalTrials.gov
percentages (40.2%
and 34.7%,
respectively) are very
similar to those in the
article, likely with a
similar test of
statistical significance.

provided for this timepoint.

provided for this timepoint.

and 72.1%,
respectively) are very
similar to those in the
article, likely with a
similar test of
statistical significance.
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Assignment, Day
4, participants
NCT00377260

Amoxicillin-Clavulanate:

Amoxicillin-Clavulanate: 67%

No

The Time to
Resolution of
Symptoms,
Defined as Acute
Otitis MediaSeverity of
Symptoms
(AOM-SOS)
Score of 0 or 1
on Two
Consecutive
Occasions,
According to
Treatment
Assignment, Day
7, participants
NCT00404079

96/144

Placebo: 53%

Placebo: 76/147

No statistical analysis

No statistical analysis

provided for this timepoint.

ClinicalTrials.gov
percentages (66.7%
and 51.7%,
respectively) are very
similar to those in the
article, likely with a
similar test of
statistical significance.

Glucosamine Sulphate: 9,

Glucosamine Sulphate: 4.8,

Yes

Roland Morris
Disability
Questionnaire, 1
year

SD: 4;

95% CI: (3.9, 5.6)

Placebo: 9, SD: 4

Placebo: 5.5, 95% CI: (4.7,

Odds Ratio: 4.5 ± 4; P=0.05

6.4)

ClinicalTrials.gov score
is higher for both trial
arms and statistical
testing results are
different in the two
sources, leading to a
difference in trial

provided for this timepoint.
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P=0.50

interpretation.

NCT00421733

Placebo: -0.03

Placebo: -3%

No

Change From
Baseline to the
Last Ontreatment
Measurement in
Urine Albumin to
Creatinine Ratio
(UACR) Levels
Determined
From the First
Morning Void
(FMV) Urine
Collections
Comparing
Placebo to the
Combined
Paricalcitol
Treatment
Groups (1 Mcg
and 2 Mcg),
mean log mg/g
creatinine

SD: 0.61

95% CI: (-16, 13)

Combined Paricalcitol 1

Combined Paricalcitol 1 Mcg

Mcg and 2 Mcg: -0.18

and 2 Mcg: -16%

Change from baseline
UACR levels are very
similar with identical
tests of significance.

SD: 0.70

95% CI: (-24, -9)

Paricalcitol 1 Mcg: -0.15

Paricalcitol 1 Mcg: -14%

SD: 0.72

95% CI: (-24, -1)

Paricalcitol 2 Mcg: -0.22

Paricalcitol 2 Mcg: -0.20%

SD: 0.69

95% CI: (-30, -8)

Placebo vs. Combined

Placebo vs. Combined

Paricalcitol 1 Mcg and 2

Paricalcitol 1 Mcg and 2 Mcg:

Mcg:

P = 0.071

P = 0.071

Placebo vs. Paricalcitol 1 Mcg:
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Placebo vs. Paricalcitol 1

P = 0.23

Mcg:

Placebo vs. Paricalcitol 2 Mcg:

P = 0.229

P = 0.053

Placebo vs. Paricalcitol 2
Mcg:
P = 0.053

NCT00426751

Eptifibatide: 124/214

Number of
Abciximab: 103/196
Participants With
Complete Sum
Adjusted Difference: 6.8%
ST Resolution
(STR) 60 Min
95% CI: (-3.0%, 16.6%)
After
Percutaneous
Coronary
Intervention
(PCI) (Intent-toTreat
Population)

Eptifibatide: 62.6%

Yes

Abciximab: 56.3%

Confidence interval of
the adjusted
difference between
arms crosses zero on
ClinicalTrials.gov and
does not in the article,
suggesting a
difference in the
statistical significance
of the results between
the sources.

Adjusted Difference: 7.1%
95% CI: (2.7%, 17.0%)
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NCT00440050

Placebo: 7.98

Placebo: 8.27

No

Rate of Change
on the ADAS-Cog
11, mean

SD: 9.84

95% CI: (6.72, 9.82)

Docosahexaenoic Acid

Docosahexaenoic Acid (DHA):

(DHA): 8.27

7.98

SD: 8.9

95% CI: (6.51, 9.45)

No statistical analysis

P = 0.41

While values appear
to be switched for the
DHA and placebo
arms between the
two sources,
interpretation is
unchanged since the
difference between
values is not
statistically significant.

provided.
NCT00440050

Placebo: 2.87

Placebo: 2.93

No

Rate of Change
on CDR-SOB

SD: 2.93

95% CI: (2.44, 3.42)

Docosahexaenoic Acid

Docosahexaenoic Acid (DHA):

(DHA): 2.93

2.87

SD: 2.83

95% CI: (2.44, 3.30)

No statistical analysis

P = 0.68

While values appear
to be switched for the
DHA and placebo
arms between the
two sources,
interpretation is
unchanged since the
difference between
values is not
statistically significant.

provided.
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NCT00484315

TAXUS Element: 51/915

TAXUS Element: 52/922

No

Target Lesion
Failure (TLF) at
12 Months Postindex Procedure,
number of
participants.

TAXUS Express: 19/309

TAXUS Express: 19/313

P = 0.9996

P = 0.78

NCT00547534

Lymphoma subjects: 13/29

Lymphoma subjects: 47% (of

Number of
participants with TLF
is similar between
sources, and both
sources report no
significant difference
between arms.
No

Number of
Participants With
Progression Free
Survival (PFS) at
2 Years

29 evaluable patients)

NCT00765817

Exenatide: -1.71

Exenatide: -1.74

Change in
Glycosylated
Hemoglobin
(HbA1c), least
squares mean

SE: 0.09

95% CI: (-1.91, -1.56)

Placebo: -1.00

Placebo: -1.04

The number of
participants with PFS
at 2 years is
approximately the
same in both sources
(45% and 47%,
respectively), even if
the reported values
were different.
No
The percentage
change in HbA1c is
very similar between
sources, with an
identical test of
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percentage

SE: 0.09

95% CI: (-1.22, -0.86)

P<0.001

P<0.001

NCT00808236

RhinoChill: 33/83

RhinoChill: 35/93

No

Achieve Return
of Spontaneous
Circulation
(ROSC)

Control: 43/99

Control: 43/101

No Statistical Analysis

P = 0.48

The number who
achieved ROSC is
similar between
sources, likely with a
similar test of
statistical significance.
No

Provided.
NCT00894543

Escitalopram: -0.53

Escitalopram: -0.52

Change in Daily
Severity of Hot
Flashes Between
Baseline and
Week 8 as
Assessed by
Prospective Daily
Diaries, mean

95% CI: (-0.64, -0.40)

95% CI: (-0.64, -0.40)

Placebo: -0.30

Placebo: -0.30

95% CI: (-0.42, -0.17)

95% CI: (-0.42, -0.17)

P<0.001

P<0.001

statistical significance.

The change in daily
severity of hot flashes
in the escitalopram
arm is very similar
between sources, and
the test of statistical
significance is
identical.

